Top

Published in:

Open Access 01-10-2006 | Diagnostic Neuroradiology

Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours

Authors: Michael D. Jenkinson, Trevor S. Smith, Kathy A. Joyce, Diane Fildes, John Broome, Daniel G. du Plessis, Brian Haylock, David J. Husband, Peter C. Warnke, Carol Walker

Published in: Neuroradiology | Issue 10/2006

Abstract

Introduction

The biological factors responsible for differential chemoresponsiveness in oligodendroglial tumours with or without the −1p/−19q genotype are unknown, but tumour vascularity may contribute. We aimed to determine whether dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) could distinguish molecular subtypes of oligodendroglial tumour, and examined the relationship between relative cerebral blood volume (rCBV) and outcome following procarbazine, lomustine and vincristine (PCV) chemotherapy.

Methods

Pretherapy rCBV was calculated and inter- and intraobserver variability assessed. Allelic imbalance in 1p36, 19q13, 17p13, 10p12–15, and 10q22–26 and p53 mutation (exons 5–8) were determined. rCBV was compared with genotype and clinicopathological characteristics (n=37) and outcome following PCV chemotherapy (n=33).

Results

1p/19q loss was seen in 6/9 grade II oligodendrogliomas, 6/14 grade II oligoastrocytomas, 4/4 grade III oligodendrogliomas, and 3/10 grade III oligoastrocytomas. rCBV measurements had good inter- and intraobserver variability, but did not distinguish histology subtype or grade. Tumours with 1p/19q loss had higher rCBV values (Student’s t-test P=0.001). Receiver operating characteristic analysis revealed a cut-off of 1.59 for identifying genotype (sensitivity 92%, specificity 76%). Tumours with high and low rCBV showed response to chemotherapy. The −1p/−19q genotype, but not rCBV, was strongly associated with response, progression-free and overall survival following PCV chemotherapy. Tumours with high rCBV and intact 1p/19q were associated with shorter progression-free and overall patient survival than those with intact 1p/19q and low rCBV or high rCBV and 1p/19q loss.

Conclusion

rCBV identifies oligodendroglial tumours with 1p/19q loss, but does not predict chemosensitivity. The prognostic significance of rCBV may differ in oligodendroglial tumours with or without the −1p/−19q genotype.

Buckner JC, Gesme D Jr, O’Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255PubMedCrossRef

Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479PubMedCrossRef

Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845PubMed

Smith JS, Perry A, Borell TJ, et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed

van den Bent MJ (2004) Advances in the biology and treatment of oligodendrogliomas. Curr Opin Neurol 17:675–680PubMedCrossRef

Sasaki H, Zlatescu MC, Betensky RA et al (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma”. J Neuropathol Exp Neurol 61:58–63PubMed

Walker C, Smith TS, Haylock B et al (2006) Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 66:1661–1667PubMedCrossRef

Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273PubMed

Keston P, Murray AD, Jackson A (2003) Cerebral perfusion imaging using contrast-enhanced MRI. Clin Radiol 58:505–513PubMedCrossRef

10.

Cha S, Knopp EA, Johnson G et al (2002) Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 223:11–29PubMed

11.

Law M, Oh S, Babb JS et al (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 238:658–667PubMed

12.

Warnke PC, Berlis A, Ostertag C (1998) Physiological characterization of malignant oligodendrogliomas responding to PCV chemotherapy. J Neurosurg 88:399A

13.

Jager HR, Waldman AD, Benton C, Fox N, Rees J (2005) Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol 26:274–278PubMed

14.

Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M (2003) Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29:462–471PubMedCrossRef

15.

Jenkinson MD, Smith TS, Joyce K et al (2005) MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 64:2085–2089PubMedCrossRef

16.

Walker C, du Plessis DG, Fildes D et al (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182–7191PubMedCrossRef

17.

Walker C, du Plessis DG, Joyce KA et al (2005) Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 57:855–865PubMedCrossRef

18.

Walker C, Haylock B, Husband D et al (2006) Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 66:1661–1667PubMedCrossRef

19.

Kleihues P, Cavanee W (eds) (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon

20.

Wetzel SG, Cha S, Johnson G et al (2002) Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224:797–803PubMed

21.

Warmuth C, Gunther M, Zimmer C (2003) Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 228:523–532PubMed

22.

Levin VA, Edwards MS, Wright DC et al (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237–244PubMed

23.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMed

24.

Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310PubMed

25.

Law M, Yang S, Wang H et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998PubMed

26.

Maia AC Jr, Malheiros SM da Rocha AJ, et al (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777–783PubMed

27.

Hakyemez B, Erdogan C, Ercan I et al (2005) High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 60:493–502PubMedCrossRef

28.

Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25:214–221PubMed

29.

Roberts HC, Roberts TP, Bollen AW et al (2001) Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 8:384–391PubMedCrossRef

30.

Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51PubMed

31.

Aronen HJ, Pardo FS, Kennedy DN et al (2000) High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 6:2189–2200PubMed

32.

Sugahara T, Korogi Y, Kochi M et al (1998) Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171:1479–1486

33.

Xu M, See SJ, Ng WH et al (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919–926; discussion 919–926PubMed

34.

Birner P, Gatterbauer B, Oberhuber G et al (2001) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165–171PubMedCrossRef

35.

Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29–35PubMedCrossRef

36.

Schiffer D, Bosone I, Dutto A, Di Vito N, Chio A (1999) The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neurooncol 44:99–107PubMedCrossRef

37.

Vaquero J, Zurita M, Morales C, Coca S (2002) Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma. Acta Neurol Scand 106:19–23PubMedCrossRef

Title: Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours
Authors: Michael D. Jenkinson
Trevor S. Smith
Kathy A. Joyce
Diane Fildes
John Broome
Daniel G. du Plessis
Brian Haylock
David J. Husband
Peter C. Warnke
Carol Walker
Publication date: 01-10-2006
Publisher: Springer-Verlag
Published in: Neuroradiology / Issue 10/2006
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-006-0122-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2006

Functional MR study of a motor task and the Tower of London task at 1.0 T

Tentorial artery embolization in tentorial dural arteriovenous fistulas

New experimental model of sinus and cortical vein thrombosis in pigs for MR imaging studies

Cortical projections to the human red nucleus: a diffusion tensor tractography study with a 1.5-T MRI machine

Meningiomas with conventional MRI findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in differentiation?

European Society of Neuroradiology (ESNR)